Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index; 21 of the 46 sources its claims cite were checked for support.

A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice

Open access
Li, Dan, Zhang, Yizhuo, Li, Shiyu, Zheng, Bin · 2023 · Frontiers in Microbiology

Abstract

Toxoplasma gondii ( T. gondii ) can infect almost all warm-blooded animals and is a major threat to global public health. Currently, there is no effective drug or vaccine for T. gondii . In this study, bioinformatics analysis on B and T cell epitopes revealed that TGGT1_316290 (TG290) had superior effects compared with the surface antigen 1 (SAG1). TG290 mRNA-LNP was constructed through the Lipid Nanoparticle (LNP) technology and intramuscularly injected into the BALB/c mice, and its immunogenicity and efficacy were explored. Analysis of antibodies, cytokines (IFN-γ, IL-12, IL-4, and IL-10), lymphocytes proliferation, cytotoxic T lymphocyte activity, dendritic cell (DC) maturation, as well as CD4 + and CD8 + T lymphocytes revealed that TG290 mRNA-LNP induced humoral and cellular immune responses in vaccinated mice. Furthermore, T-Box 21 (T-bet), nuclear factor kappa B (NF-kB) p65, and interferon regulatory factor 8 (IRF8) subunit were over-expressed in the TG290 mRNA-LNP-immunized group. The survival time of mice injected with TG290 mRNA-LNP was significantly longer (18.7 ± 3 days) compared with the survival of mice of the control groups ( p < 0.0001). In addition, adoptive immunization using 300 μl serum and lymphocytes (5*10 7 ) of mice immunized with TG290 mRNA-LNP significantly prolonged the survival time of these mice. This study demonstrates that TG290 mRNA-LNP induces specific immune response against T. gondii and may be a potential toxoplasmosis vaccine candidate for this infection.

Overview

CoChat Summary

## TL;DR

TG290 (TGGT1_316290) mRNA-LNP vaccination in BALB/c mice induced both humoral and cellular immune responses against *Toxoplasma gondii* and prolonged survival after lethal RH-strain challenge. The study presents TG290 as a promising toxoplasmosis vaccine candidate based on epitope prediction, in vitro expression, and mouse immunization experiments.

## Key findings

  • Bioinformatics analysis suggested TG290 had better predicted linear B-cell epitope properties than SAG1, with higher surface probability, antigenic index, flexibility, and hydrophilicity; for T-cell epitopes, TG290 showed lower predicted IC50 values for H2-Iad and H2-Ied than SAG1.
  • The TG290 mRNA-LNP formulation had an encapsulation efficiency of 95.8% and induced TG290 protein expression in transfected HEK293 cells and C2C12 cells.
  • Vaccinated mice had significantly higher TG290-specific antibodies than controls: total IgG increased with the number of injections, and IgG1 and IgG2a were both elevated; the paper reports IgG2a at 0.86 ± 0.01 and IgG1 at 0.47 ± 0.01.
  • Immune readouts were increased in vaccinated mice, including IFN-γ (874.6 ± 27.1 pg/ml), IL-12 (790.6 ± 9.8 pg/ml), IL-4 (138.8 ± 1.7 pg/ml), IL-10 (265.9 ± 2.3 pg/ml), lymphocyte proliferation (SI 2.1 ± 0.06), CTL activity, CD4+ and CD8+ T cells, and DC markers CD83/CD86 and MHC-I/MHC-II.
  • After challenge with 100 RH tachyzoites, TG290 mRNA-LNP-vaccinated mice survived longer (18.5 ± 3 days; abstract also reports 18.7 ± 3 days) than blank and LNP controls, which died within 8 days; adoptive transfer of immune serum or splenocytes also prolonged survival (11.9 ± 2.6 days and 14.4 ± 2.5 days, respectively).

## Methods

  • Design: preclinical vaccine study combining epitope prediction, mRNA-LNP vaccine construction, in vitro expression testing, mouse immunization, immune assays, and lethal parasite challenge.
  • Sample/data: seven-week-old male BALB/c mice (n = 60) split into TG290 mRNA-LNP, empty LNP, and blank groups; additional naive mice (n = 30) were used for adoptive transfer experiments. HEK293, C2C12, Vero, and Sp2/0 cells were used for transfection/expression and CTL assays.
  • Main analysis: ELISA for TG290-specific antibodies, cytokine ELISAs, lymphocyte proliferation assays, CTL assays, flow cytometry for T cells and dendritic-cell markers, qRT-PCR/western blot for IRF8, T-bet, and NF-κB p65, and survival analysis using log-rank tests.

## Limitations

  • The paper states that all vaccinated and adoptively immunized mice eventually died after lethal RH challenge, so the vaccine prolonged survival but did not provide complete protection.
  • Evident from the text: the efficacy was tested only in female/male? male BALB/c mice are explicitly mentioned here, under a single mouse strain and against the highly virulent RH strain, so generalizability to other hosts, parasite strains, or protective endpoints is not established.
  • Evident from the text: the study is preclinical and does not report human data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fmicb.2023.1145114

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Comparison of linear-B cell epitopes of TG290 and SAG1 in terms of DNASTAR predictions of hydrophilicity, flexible regions, antigenic index, and surface probability.
Figure 1 Comparison of linear-B cell epitopes of TG290 and SAG1 in terms of DNASTAR predictions of hydrophilicity, flexible regions, antigenic index, and surface probability.CC BY · PubMed Central
Figure 2 The construction, protein expression and delivery of TG290 mRNA-LNP vaccine. (A) The engineered mRNA construct. An mRNA encoding the TG290 was designed with 5′ and 3′ untranslated regions (UTRs) flanking the coding sequence, a 5′ cap-1 structure and a 3′ poly(A) tail. In vitro-synthesized mRNA encapsulated in a lipid nanoparticle to be applied in in vitro and in vivo experiments. (B) The expression of TG290 in HEK293 cell lysates and STAg was determined by Western blot. rTG290 served as a positive control; STAg: (soluble antigen of T. gondii); Blank: non-transfected cells; Unpurified cell lysate from TG290 mRNA-transfected cells ©; Purified supernatant from TG290 mRNA-transfected cells (pTM). (C) In vitro-synthesized TG290 mRNA was encapsulated in a lipid nanoparticle and administered to C2C12 cells. Lysate was analyzed by Western blotting with Rabbit anti-TG290 pAb. Blank: empty transfected cells; TG290 mRNA-LNP transfected cells (TML).
Figure 2 The construction, protein expression and delivery of TG290 mRNA-LNP vaccine. (A) The engineered mRNA construct. An mRNA encoding the TG290 was designed with 5′ and 3′ untranslated regions (UTRs) flanking the coding sequence, a 5′ cap-1 structure and a 3′ poly(A) tail. In vitro-synthesized mRNA encapsulated in a lipid nanoparticle to be applied in in vitro and in vivo experiments. (B) The expression of TG290 in HEK293 cell lysates and STAg was determined by Western blot. rTG290 served as a positive control; STAg: (soluble antigen of T. gondii); Blank: non-transfected cells; Unpurified cell lysate from TG290 mRNA-transfected cells ©; Purified supernatant from TG290 mRNA-transfected cells (pTM). (C) In vitro-synthesized TG290 mRNA was encapsulated in a lipid nanoparticle and administered to C2C12 cells. Lysate was analyzed by Western blotting with Rabbit anti-TG290 pAb. Blank: empty transfected cells; TG290 mRNA-LNP transfected cells (TML).CC BY · PubMed Central
Figure 3 TG290 mRNA-LNP vaccine elicited humoral immunity response in BALB/c mice. (A) Total TG290-specific IgG; (B) TG290-specific IgG1, IgG2a. The OD450 value of total TG290-specific IgG was recorded at 0-, 2-, 4-, and 6-weeks post-vaccination (n = 10). The OD450 value of TG290-specific IgG subclass (IgG1, IgG2a) was recorded at 6 weeks post-vaccination (n = 5). ****p < 0.0001, analyzed by One-way ANOVA with multiple comparisons (compare the mean of each group with the mean of every other group).
Figure 3 TG290 mRNA-LNP vaccine elicited humoral immunity response in BALB/c mice. (A) Total TG290-specific IgG; (B) TG290-specific IgG1, IgG2a. The OD450 value of total TG290-specific IgG was recorded at 0-, 2-, 4-, and 6-weeks post-vaccination (n = 10). The OD450 value of TG290-specific IgG subclass (IgG1, IgG2a) was recorded at 6 weeks post-vaccination (n = 5). ****p < 0.0001, analyzed by One-way ANOVA with multiple comparisons (compare the mean of each group with the mean of every other group).CC BY · PubMed Central
Figure 4 The determination of cytokines. The prepared spleen cell suspension was obtained from mice 2 weeks of the last vaccination. The levels of (A) IFN-γ and (B) IL-12 and (C) IL-4 and (D) IL-10 in BALB/c mice immunized with TG290 mRNA-LNP vaccine. Data were obtained from triplicate independent experiments and are presented as means ± SD (n = 5). ****p < 0.0001, analyzed by one-way ANOVA multiple comparisons (compare the mean of each group with the mean of every other group).
Figure 4 The determination of cytokines. The prepared spleen cell suspension was obtained from mice 2 weeks of the last vaccination. The levels of (A) IFN-γ and (B) IL-12 and (C) IL-4 and (D) IL-10 in BALB/c mice immunized with TG290 mRNA-LNP vaccine. Data were obtained from triplicate independent experiments and are presented as means ± SD (n = 5). ****p < 0.0001, analyzed by one-way ANOVA multiple comparisons (compare the mean of each group with the mean of every other group).CC BY · PubMed Central
Figure 5 Proliferation and CTL activity of lymphocytes in immunized BALB/c mice. (A) The proliferative responses of splenocytes in immunized BALB/c mice. SI, stimulation index. (B) CTL activity of spleen lymphocytes in TG290 mRNA-LNP immunized mice. The horizontal axis indicates the effector-to-target cell ratios. The vertical axis shows the percentage of T. gondii-specific lysis. Data were obtained from triplicate independent experiments and are presented as means ± SD (n = 5). ****p < 0.0001, analyzed by One-way ANOVA with multiple comparisons (compare the mean of each group with the mean of every other group).
Figure 5 Proliferation and CTL activity of lymphocytes in immunized BALB/c mice. (A) The proliferative responses of splenocytes in immunized BALB/c mice. SI, stimulation index. (B) CTL activity of spleen lymphocytes in TG290 mRNA-LNP immunized mice. The horizontal axis indicates the effector-to-target cell ratios. The vertical axis shows the percentage of T. gondii-specific lysis. Data were obtained from triplicate independent experiments and are presented as means ± SD (n = 5). ****p < 0.0001, analyzed by One-way ANOVA with multiple comparisons (compare the mean of each group with the mean of every other group).CC BY · PubMed Central
Figure 6 Flow cytometry analysis. The percentage of CD4+ (A) and CD8+ T lymphocytes (B) in splenic lymphocytes. The percentage of CD83 (C) and CD86 molecules (D) on splenic DCs. The percentage of MHC-I (E) and MHC-II molecules (F) on splenic DCs. n = 5; ****p < 0.0001, analyzed by One-way ANOVA with multiple comparisons (compare the mean of each group with the mean of every other group).
Figure 6 Flow cytometry analysis. The percentage of CD4+ (A) and CD8+ T lymphocytes (B) in splenic lymphocytes. The percentage of CD83 (C) and CD86 molecules (D) on splenic DCs. The percentage of MHC-I (E) and MHC-II molecules (F) on splenic DCs. n = 5; ****p < 0.0001, analyzed by One-way ANOVA with multiple comparisons (compare the mean of each group with the mean of every other group).CC BY · PubMed Central
Figure 7 The mRNA and protein expression levels of IRF8, T-bet, and p65 in splenocytes. (A) The mRNA expression levels of IRF8, T-bet, and p65. (B) The protein expression levels of IRF8, T-bet, and p65. Data were obtained from triplicate independent experiments and are presented as means ± SD (n = 5). ****p < 0.0001, analyzed by One-way ANOVA with multiple comparisons (compare the mean of each group with the mean of every other group).
Figure 7 The mRNA and protein expression levels of IRF8, T-bet, and p65 in splenocytes. (A) The mRNA expression levels of IRF8, T-bet, and p65. (B) The protein expression levels of IRF8, T-bet, and p65. Data were obtained from triplicate independent experiments and are presented as means ± SD (n = 5). ****p < 0.0001, analyzed by One-way ANOVA with multiple comparisons (compare the mean of each group with the mean of every other group).CC BY · PubMed Central
Figure 8 Survival curves of BALB/c mice after challenge. (A) TG290 mRNA-LNP vaccine protected against the lethal challenge (15 mice per group). (B) Adoptive immunization with serum protected against the lethal challenge (10 mice per group). (C) Adoptive immunization with lymphocytes protected against the lethal challenge (10 mice per group). ****p < 0.0001 by the log rank tests.
Figure 8 Survival curves of BALB/c mice after challenge. (A) TG290 mRNA-LNP vaccine protected against the lethal challenge (15 mice per group). (B) Adoptive immunization with serum protected against the lethal challenge (10 mice per group). (C) Adoptive immunization with lymphocytes protected against the lethal challenge (10 mice per group). ****p < 0.0001 by the log rank tests.CC BY · PubMed Central

Verification

Claims the paper makes

18 Valid · 2 Not valid · 22 Not checked · 51 Own results and interpretations

38 more claims

Create a free account to see all 93 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 27
  • Probably not a substantial claim. 37

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 64 references

Cited by

See all 22

Metadata

Authors
Li, D., Zhang, Y., Li, S., & Zheng, B.
Affiliations
Hangzhou Medical College (CN)
Corresponding author
Zheng, Bin
Venue
Frontiers in Microbiology
Published
2023-03-21
Volume
14
Pages
1145114-1145114
ISSN
1664-302X (ISSN-L)
OpenAlex
W4328114905
Cited by
22
References
64
Citations by year
2026: 8 · 2025: 7 · 2024: 6 · 2023: 1
FWCI
5.14
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Microbiology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (32000293)
Topics
  • Life Sciences › Immunology and Microbiology › Parasitology › Toxoplasma gondii Research Studies
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords
Toxoplasma gondii, toxoplasmosis, mRNA-LNP vaccine, B and T cell epitopes, SAG1, humoral and cellular immune response, cytotoxic T lymphocytes, dendritic cell maturation, T-bet, NF-κB p65, IRF8, vaccine candidate, adoptive immunization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice. https://app.cochat.ai/papers/10.3389/fmicb.2023.1145114
The paper
Li, D., Zhang, Y., Li, S., & Zheng, B. (2023). A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2023.1145114

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.